[144] Edwards Lifesciences Corp SEC Filing

Rhea-AI Filing Summary

Edwards Lifesciences (EW) reported a planned sale under Form 144. The notice covers up to 20,700 common shares with an aggregate market value of $1,719,841.00, to be executed through Charles Schwab on or about 11/10/2025 on the NYSE. The seller acquired the shares via an employee stock option exercise with a broker payment for cashless exercise on the same date. Shares outstanding were 580,300,000 at the time cited.

Insights

Securities law analyst

Administrative Form 144 notice for potential insider share sales.

This filing states an intent to sell up to 20,700 shares of Edwards Lifesciences common stock with an aggregate market value of $1,719,841.00. It identifies the broker (Charles Schwab), the exchange (NYSE), and an approximate sale date of 11/10/2025. The shares were obtained via an employee stock option exercise using a cashless method.

Form 144 is a notice requirement for affiliates or holders of restricted securities. It permits sales under Rule 144 but does not guarantee that sales will occur or at specific prices. Actual market impact, if any, depends on whether, when, and how the shares are sold.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	20700	1719841.00	580300000	11/10/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/10/2025	Employee Stock Option Exercise - See Remarks	EDWARDS LIFESCIENCES CORPORATION			20700	11/10/2025	Broker Payment for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did Edwards Lifesciences (EW) file?

A Form 144 notice indicating a potential sale of restricted or control securities under Rule 144.

How many EW shares are covered by the Form 144?

Up to 20,700 common shares.

What is the aggregate market value of the planned sale?

$1,719,841.00 for the shares listed in the notice.

When could the EW shares be sold and on which exchange?

Approximately on 11/10/2025 on the NYSE.

How were the shares acquired by the seller?

Through an employee stock option exercise with a broker payment for cashless exercise on 11/10/2025.

How many EW shares were outstanding as cited?

580,300,000 shares outstanding were listed in the notice.